COMMUNIQUÉS West-GlobeNewswire

AID FOR AIDS and AID FOR LIFE to Celebrate 30 Years of Global Humanitarian Impact at My Hero Gala in New York
05/10/2026
“Dignity Across Borders” Gala Will Honor Edgar Ramírez, Nathalie Rayes, Maria Eugenia Maury and Mary Ann Torres, While Raising Critical Funds for HIV Treatment, Migrant Integration and Earthquake Recovery in Venezuela [...]
Cannara étend son entente d’approvisionnement international avec Curaleaf
05/10/2026
MONTRÉAL, 05 oct. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), un producteur verticalement intégré de [...]
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
05/10/2026
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the [...]
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
05/10/2026
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development
05/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today [...]
OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting
05/10/2026
Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 At the September 23, 2026, data cutoff, CUSP06 achieved a 62% objective response [...]
Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer
05/10/2026
Appointment solidifies Cerevance’s leadership team as the company advances solengepras through Phase 3 development in Parkinson’s disease BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage [...]
Averly Health launches to transform cardiometabolic care in the UK
05/10/2026
Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will set a new standard for access and outcomes to transform the [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
05/10/2026
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
05/10/2026
MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
05/10/2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related matters at the [...]
Flyte Aviation Launches Under NYSE American Ticker “VJET”
05/10/2026
Flyte Believes Its Proprietary Technology, Data, and Digital Booking Platform Can Disrupt the $11.6 Billion US Private Jet Charter Market Company believes its newly built AI-technology stack can fundamentally transform [...]
Digbi Health Study of Nearly 16,000 Members Finds Precision Biology GI Care Delivers IBS Relief at Scale
05/10/2026
Combining Gut microbiome, genetic, and glucose signals delivers unprecedented personalized care to bring clinically meaningful relief to more than half of symptomatic members MOUNTAIN VIEW, Calif., Oct. 05, 2026 (GLOBE [...]
Upgrade of revenue and operating profit guidance
05/10/2026
ANNOUNCEMENT NO. 317 5 October 2026 ChemoMetec maintained its positive momentum in the first quarter of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with the NC-203 being a [...]
Elevate Holistics Launches Telehealth Platform for At-Home, Low-Dose Ketamine Care
05/10/2026
Tulsa, Oklahoma, Oct. 04, 2026 (GLOBE NEWSWIRE) -- Elevate Holistics , a telehealth provider focused on accessible, clinician-guided wellness care, announces the launch of its online ketamine telehealth platform, [...]
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
04/10/2026
SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8: [...]
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
05/10/2026
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease MILAN, Oct. 04, 2026 (GLOBE [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
03/10/2026
Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in [...]

Pages